Table 2.
Relationship of Koff and T1/2 of ABDs and clinical efficacy of CARTs.
| Target | mAbs | Kon | Koff | KD (nM) | T1/2 (second) | Efficacy (PR+CR)% (Responder/total patients) |
|---|---|---|---|---|---|---|
| PMSA | 3D8 (133) | 6.04e+6 | 1.36e-1 | 22.52 | 5 | 40 (2/5) |
| J591 (137) | 1.02e+5 | 1.23e-4 | 1.21 | 5,634 | 0 (0/20) | |
| GD2 | 14.G2a (95) | 1.5e+5 | 1.12e-2 | 74.67 | 62 | 30 (10/33) |
| Hu3F8 (95) | 9.19e+4 | 1.03e-3 | 10.4 | 673 | 0 (0/10) | |
| KM8138 (106) | 1.14e+4 | 1.7e-3 | 149 | 407 | 0 (0/12) | |
| Mesothelin | M5* | 4.2e+4 | 1.13e-3 | 26.9 | 613 | 0 (0/17) |
| SS1* | 5.55e+6 | 5.60e-4 | 0.1 | 1,237 | 2.7 (1/27) |
*The Kon, Koff, KD, and T1/2 of mAbs M5 and SS1 were from Patent: WO2015090230A1. The clinical trial reference was the same as Table 1 .